Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Between a rock and a hard place?

Adrian Whitty1, Gnanasambandam Kumaravel

  • 1Drug Discovery Department, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. adrian.whitty@biogenidec.com

Nature Chemical Biology
|February 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein-ligand binding kinetics are primarily controlled by the protein, not the ligand.

bioRxiv : the preprint server for biology·2026
Same author

A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells.

Nature communications·2025
Same author

Impact of Protein Conformational Diversity on Structure-Based Prediction of Druggability.

Journal of chemical information and modeling·2025
Same author

Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors.

Journal of medicinal chemistry·2025
Same author

Getting Started with Machine Learning for Experimental Biochemists and Other Molecular Scientists.

Current protocols·2025
Same author

MEnTaT: A machine-learning approach for the identification of mutations to increase protein stability.

Proceedings of the National Academy of Sciences of the United States of America·2023

Developing small-molecule inhibitors for protein-protein interactions is challenging but advancing. New knowledge and tools offer hope, though significant hurdles persist in drug discovery.

Area of Science:

  • Drug discovery and development
  • Medicinal chemistry
  • Molecular biology

Background:

  • Targeting protein-protein interactions (PPIs) with small molecules is a complex area of drug discovery.
  • Historically, PPIs have been considered "undruggable" targets due to their large, relatively flat interaction surfaces.

Purpose of the Study:

  • To review the challenges and recent advancements in developing small-molecule inhibitors against PPI targets.
  • To highlight the evolving landscape of tools and knowledge for tackling these difficult targets.

Main Methods:

  • Review of current scientific literature and research in small-molecule drug discovery.
  • Analysis of emerging strategies and technologies for targeting protein-protein interactions.
  • Synthesis of findings on the successes and limitations in the field.

Related Experiment Videos

Main Results:

  • Significant challenges remain in designing effective small-molecule inhibitors for PPIs.
  • Recent progress in understanding PPIs and developing novel chemical approaches offers renewed optimism.
  • The field is benefiting from advancements in structural biology, computational chemistry, and screening technologies.

Conclusions:

  • Despite inherent difficulties, the development of small-molecule PPI inhibitors is a promising area of research.
  • Continued innovation in chemical biology and drug design is crucial for overcoming existing obstacles.
  • Further research holds potential for novel therapeutics targeting previously intractable diseases.